THOUSAND OAKS, Calif., April 26, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the imminent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for teprotumumab, a fully human monoclonal antibody and targeted inhibitor of the insulin-like growth factor-1 receptor (IGF-1R), for the treatment of moderate to severe Thyroid Eye Disease (TED) in adults. TED is a serious, progressive, debilitating and potentially vision-threatening autoimmune disease that can cause proptosis (eye bulging), diplopia (double vision), eye pain, redness and swelling.1 If approved, teprotumumab would be the first and only medicine approved for TED in the European Union.
Amgen CEO Robert Bradway scored a 5.8% increase in overall compensation last year mostly thanks to the company’s acquisition of Horizon Therapeutics.
Viatris, eyeing a return to growth, taps Moderna, Amgen alum as Cco
Amgen employees star in the biopharma’s newest social media video, adopting a popular TikTok trend known as “Of course,” as it builds out a social strategy combining popular trends and homegrown content.
April 4 (Reuters) - Boehringer Ingelheim on Thursday said it will lay off some of its salesforce due to poor U.S. sales of its biosimilar version of AbbVie’s (ABBV.N), opens new tab blockbuster arthritis treatment Humira.
As negotiators hash out prices for certain top-selling Medicare Part D drugs, the maximum fair price (MFP) could ultimately be far below the actual value that the drug offers to patients, according to researchers at the Tufts Center for the Study of Drug Development (CSDD).It’s also not entirely clear which costs CMS will take into account during the negotiations.nA CMS guidance released in 2023 sought to clarify the issue but there are still ambiguities surrounding the eligible costs for the purposes of the price negotiations introduced in the Inflation Reduction Act, said Ken Getz, executive director, and Emily Botto, a senior research analyst at CSDD, in a March 28 webinar hosted by FDAnews, a WCG company.nFor example, the CMS guidance offered no explicit direction on how long the timeline is for the inclusion of direct costs.
Bristol Myers Squibb looks on track to overtake Amgen as the KRAS leader in lung cancer after following up its rival’s FDA setback with a positive confirmatory trial readout.
In lawsuit, Amgen slams Colorado`s proposed Enbrel price cap